Astellas, Dell Of U.S. To Partner On Cancer-Drug Biomarkers
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Dell Signaling Technology of the United States signed a partnership agreement to collaborate on research for biomarkers to serve as diagnostic reagents, beginning with those leading to cancer drugs
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.